Navigation Links
Possible treatment for serious blood cancer
Date:5/6/2013

A single antibody could be the key to treating multiple myeloma, or cancer of the blood, currently without cure or long-term treatment.

"We tested the antibody in various ways, including on tumour cells from myeloma patients that have been transplanted into mice. The tests showed that the antibody is able to destroy myeloma cells", explains Markus Hansson, a researcher at Lund University in Sweden.

Using a 'biological library' of thousands of antibodies from the company BioInvent in Lund, the team singled out antibody BI-505, shown to have a powerful effect on the tumour cells in both cell studies and animal experiments. It has also been tested in an initial safety study on seriously ill patients, and a study of its treatment effects has just started.

"This study will include patients who have just been diagnosed and therefore still feel fairly well. We want to test the antibody treatment before the patients are treated with any other drugs", says Markus Hansson.

Today there are a number of drugs to treat multiple myeloma, but no cure. None of the drugs are able to eradicate the disease, meaning cancer cells increase in number after a period of remission. Survival has been extended with new treatments, but less than half of all patients live longer than five years from diagnosis.

Myeloma occurs when a specific type of cell in the bone marrow is converted into tumour cells. Blood formation is disrupted and patients suffer from a lack of blood resulting in fatigue. The bones can be weakened with a risk of fractures and compacted vertebrae, and patients sometimes suffer kidney failure as a result of the disease.

Antibodies are a part of the immune system, fighting off foreign bodies. Antibody-based drugs are now used to treat certain inflammatory diseases and types of cancer.

The treatment study in Lund will involve 15 patients and is expected to be completed this year. If the results are good, Markus Hansson and his colleagues hope to be able to continue testing BI-505 in larger-scale studies. They will be studying the best way of using the new antibody: alone or in combination with other drugs; at the start of the disease or at a later stage.


'/>"/>

Contact: Markus Hansson
markus.hansson@med.lu.se
46-705-931-110
Lund University
Source:Eurekalert

Related medicine news :

1. Zamansky & Associates LLC Investigates Chemed Corporation For Possible Securities Law Violations And Breaches Of Fiduciary Duties To Shareholders
2. US Drug Watchdog Is Expanding Their Transvaginal Mesh Failure Initiative And They Are Urging Victims To Call Them For The Names Of The Best Possible Women Lawyers To Help
3. Lung Cancer Asbestos Victims Center Now Urges Any Type Of Lung Cancer Victim Who Was Exposed To Asbestos At Work To Call Them About Possible Significant Compensation
4. Personal Injury Lawyer Sean M. Cleary Warns Resort Vacationers about Possible Accidents and Injuries
5. Lung Cancer Asbestos Victims Center Now Urges All Lung Cancer Victims To Call Them If They Were Exposed To Asbestos In Their Place Of Work-Possible Major Compensation
6. Pancreatic Cancer Correlation to Type 2 Diabetes Drugs Januvia and Byetta, New Studies Find Possible Connection
7. Lung Cancer Asbestos Victims Center Now Urges All US Citizens With Any Type Of Lung Cancer To Call Them About Possible Compensation-Were You Exposed To Asbestos
8. Lung Cancer Asbestos Victims Center Now Urges Lung Cancer Victims Who Are Nonsmokers And Were Exposed To Asbestos On The Job To Call Them-Possible Major Compensation
9. Battle for Grace: A Memoir of Pain, Redemption and Impossible Love
10. US Drug Watchdog Now Urges Transvaginal Mesh Failure Victims With A Failed Revision Surgery to Call Them for the Names of the Best Possible Women Attorneys
11. Lung Cancer Asbestos Victims Center Now Urges Nonsmoker Lung Cancer Victims Who Were exposed To Asbestos In Their Workplace To Call Them About Possible Compensation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ... committed to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne ... (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced today. , ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting ... Invisalign® in Lutz, FL. With the help of this highly-effective, yet convenient system, ... potential complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the thriving ... and head shops –can’t help but be heartened by the industry’s current surge. But ... aptly described as “skunk smell.” At last they can simply, safely and effectively ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
(Date:4/24/2017)... ... 24, 2017 , ... The Santana Telehealth Project was honored with the 2017 ... American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. , “I am ... the lives of the poor and underserved in other parts of the world,” said ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... , April 24, 2017 Solentim, ... today announced the addition of a major new ... In-situ Plate Seeding,). The VIPS has been developed ... 384 well microplates as part of the process ... offers a simple and more reliable solution when ...
(Date:4/20/2017)... PLANO, Texas , April 20, 2017  Vivify ... via mobile devices, has been awarded a very significant ... care via EMRs to continual care via digital health. ... of key intellectual property and further secures Vivify,s position ... Vivify, launched in 2009, was the first company to ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Company,s consumer product development program, based on ... Society for Investigative Dermatology (SID) 76 th ... and promote the sciences relevant to skin health ...
Breaking Medicine Technology: